| Literature DB >> 23025471 |
Adalbjorg Kristbjornsdottir1, Vilhjalmur Rafnsson.
Abstract
BACKGROUND: Residents of geothermal areas are exposed to geothermal emissions and water containing hydrogen sulphide and radon. We aim to study the association of the residence in high temperature geothermal area with the risk of cancer.Entities:
Mesh:
Year: 2012 PMID: 23025471 PMCID: PMC3511870 DOI: 10.1186/1476-069X-11-73
Source DB: PubMed Journal: Environ Health ISSN: 1476-069X Impact factor: 5.984
Figure 1Geological map of Iceland, showing the distribution of natural geothermal activity and the age of bedrock. Modified with permission from National Energy Authority. Small circles low temperature geothermal field, large circles high temperature geothermal field, age of bedrock: < 0.8, to gray 0.8-3.3, to light gray 3.3-15, and white glaciers.
Figure 2Map of Iceland, showing the study areas according to the community codes: 1) High-temperature geothermal area. 2) Cold reference area. 3) Warm reference area. 4) Capital and South West area. 5) Uninhabited area. Modified with permission from National Land Survey of Iceland.
Baseline characteristics in the high-temperature geothermal areas and different reference areas according to census 1981
| Number of people | 1,497 (100) | 50,878 (100) | 22,431 (100) |
| | | | |
| Men | 767 (51.2) | 26,431 (51.9) | 11,929 (53.2) |
| Woman | 730 (48.8) | 24,447 (48.1) | 10,502 (46.8) |
| | | | |
| Mean ± SD | 29.69 ± 17.22 | 28.12 ± 16.28 | 28.06 ± 16.20 |
| Median, IQR (0.25 ; 0.75) | 27 (15 ; 43) | 25 (15 ; 40) | 25 (15 ; 39) |
| | | | |
| Basic education | 368 (24.6) | 13,831 (27.2) | 6,565 (29.3) |
| Medium education | 428 (28.6) | 13,414 (26.4) | 5,665 (25.3) |
| Academic education | 140 (9.4) | 3,653 (7.2) | 1,428 (6.4) |
| Unclassified | 535 (35.7) | 19,404 (38.1) | 8,481 (37.7) |
| Missing | 36 (1.7) | 576 (1.1) | 292 (1.3) |
| | | | |
| Single family home | 1,205 (80.5) | 33,761 (66.4) | 17,343 (77.3) |
| Other type of house | 292 (19.5) | 17,117 (33.6) | 5,088 (22.7) |
| | | | |
| Capital region | 0 | 0 | 0 |
| Other urban regions | 0 | 20,958 (41.2) | 4,863 (21.7) |
| Rural regions | 1,497 (100.0) | 29,920 (58.8) | 17,568 (78.3) |
Abbreviations: SD standard deviation, IQR interquartile range.
Number of all cancers and selected cancer sites among men and women combined in the high-temperature geothermal areas, hazard ratio (HR), 95% confidence intervals (CI) according to compared with the populations in warm reference area and cold reference area, adjusted for age, gender, education, and type of housing
| | |||||
|---|---|---|---|---|---|
| All sites (C00-C97 and D45-D47) | 184 | ||||
| Lip, oral cavity, and pharynx (C00-C14) | 2 | 0.64 | 0.16 to 2.60 | 0.81 | 0.20 to 3.38 |
| Oesophagus (C15) | 1 | 0.50 | 0.07 to 3.58 | 0.58 | 0.08 to 4.20 |
| Stomach (C16) | 7 | 1.13 | 0.53 to 2.41 | 0.99 | 0.46 to 2.14 |
| Colon, rectum, and anus (C18-C21) | 16 | 1.13 | 0.69 to 1.86 | 1.17 | 0.70 to 1.94 |
| Bile and liver (C22-C24) | 2 | 0.95 | 0.23 to 3.88 | 1.02 | 0.24 to 4.29 |
| Pancreas (C25) | 9 | ||||
| Nasal cavity and middle ear (C30) | 1 | 3.32 | 0.42 to 26.32 | 2.58 | 0.30 to 22.33 |
| Larynx (C32) | 2 | 2.21 | 0.53 to 9.30 | 3.04 | 0.66 to 13.98 |
| Lung and bronchus (C33-C34) | 20 | 1.24 | 0.80 to 1.95 | 1.11 | 0.70 to 1.75 |
| Bone (C40-C41) | 2 | 3.56 | 0.83 to 15.27 | ||
| Melanoma (C43) | 2 | 0.51 | 0.13 to 2.04 | 0.62 | 0.15 to 2.56 |
| Other cancer of skin (C44) | 4 | 0.84 | 0.31 to 2.27 | 1.01 | 0.37 to 2.79 |
| Soft tissue sarcoma (C49) | 2 | 1.86 | 0.45 to 7.78 | 1.97 | 0.45 to 8.66 |
| Breast (C50) | 31 | ||||
| Vulva (C51) | 1 | 4.03 | 0.50 to 32.36 | 2.96 | 0.34 to 25.58 |
| Cervix uteri (C53) | 2 | 0.85 | 0.21 to 3.45 | 1.04 | 0.25 to 4.37 |
| Uterus (C54-C55) | 3 | 0.82 | 0.26 to 2.60 | 0.88 | 0.27 to 2.82 |
| Ovary (C56-C57) | 5 | 1.25 | 0.51 to 3.05 | 1.25 | 0.50 to 3.12 |
| Prostate (C61) | 29 | 1.16 | 0.80 to 1.68 | 1.37 | 0.93 to 2.00 |
| Kidney (C64-C66) | 5 | 0.67 | 0.28 to 1.62 | 0.83 | 0.34 to 2.04 |
| Bladder (C67) | 8 | 1.12 | 0.56 to 2.28 | 1.02 | 0.50 to 2.10 |
| Brain and central nervous system (C70-C72, C75.1 and C75.3) | 5 | 0.82 | 0.34 to 2.00 | 0.90 | 0.37 to 2.23 |
| Thyroid gland (C73) | 6 | 1.51 | 0.66 to 3.42 | 1.51 | 0.65 to 3.50 |
| Cancer without specification of site (C80) | 1 | 0.32 | 0.04 to 2.26 | 0.28 | 0.04 to 2.05 |
| Lymphoid and haematopoietic tissue (C81-C96 and D45-D47) | 18 | 1.53 | 0.95 to 2.46 | ||
| Hodgkins lymphoma (C81) | 1 | 1.03 | 0.14 to 7.56 | 1.50 | 0.19 to 11.61 |
| Non-Hodgkins lymphoma (C82-C85) | 12 | ||||
| Immunoproliferative diseases (C88) | 1 | 1.31 | 0.18 to 9.76 | 2.00 | 0.24 to 16.40 |
| Leukaemia (C91-C95 and D45-D47) | 4 | 1.07 | 0.39 to 2.89 | 1.07 | 0.39 to 2.95 |
| Chronic lymphocytic leukaemia (CLL)(C91.1) | 1 | 0.76 | 0.10 to 5.54 | 0.70 | 0.09 to 5.24 |
| Non-CLL (C91-C95 and D45-D47, except C91.1) | 3 | 1.23 | 0.39 to 3.90 | 1.30 | 0.40 to 4.22 |
| p-yr 36,606 | p-yr 1320,220 | | p-yr 581,772 | | |
| Basal cell carcinoma of the skin | 30 | 1.37 | 0.95 to 1.97 | ||
Abbreviation: p-yr, person years.
Statistically significant HRs are bolded.
* 95% CI computed with bootstrap method were wide and included unity.
Number of all cancers and selected cancer sites among men only in the high - temperature geothermal areas, hazard ratio (HR), 95% confidence intervals (CI) according to comparison with the populations in warm reference area and cold reference area, adjusted for age, gender, education, and type of housing
| | |||||
|---|---|---|---|---|---|
| All sites (C00-C97 and D45-D47) | 90 | 1.06 | 0.86 to 1.30 | 1.14 | 0.92 to 1.42 |
| Lip, oral cavity, and pharynx (C00-C14) | 2 | 0.99 | 0.24 to 4.03 | 1.14 | 0.27 to 4.82 |
| Oesophagus (C15) | 1 | 0.63 | 0.09 to 4.55 | 0.91 | 0.12 to 6.86 |
| Stomach (C16) | 4 | 1.02 | 0.38 to 2.77 | 0.78 | 0.29 to 2.14 |
| Colon, rectum, and anus (C18-C21) | 9 | 1.12 | 0.58 to 2.18 | 1.14 | 0.58 to 2.25 |
| Bile and liver (C22-C24) | 1 | 0.68 | 0.09 to 4.93 | 1.37 | 0.17 to 10.83 |
| Pancreas (C25) | 5 | ||||
| Nasal cavity and middle ear (C30) | 1 | 6.46 | 0.75 to 55.75 | 13.08 | 0.79 to 215.51 |
| Larynx (C32) | 2 | 2.78 | 0.65 to 11.81 | 4.30 | 0.89 to 20.84 |
| Lung and bronchus (C33-C34) | 9 | 1.00 | 0.52 to 1.94 | 0.95 | 0.48 to 1.86 |
| Other cancer of skin (C44) | 3 | 1.12 | 0.35 to 3.54 | 1.22 | 0.38 to 3.98 |
| Soft tissue sarcoma (C49) | 1 | 1.62 | 0.22 to 12.13 | 2.52 | 0.30 to 21.04 |
| Prostate (C61) | 29 | 1.16 | 0.80 to 1.68 | 1.37 | 0.93 to 2.00 |
| Kidney (C64-C66) | 2 | 0.43 | 0.11 to 1.74 | 0.54 | 0.13 to 2.22 |
| Bladder (C67) | 7 | 1.24 | 0.58 to 2.65 | 1.11 | 0.52 to 2.41 |
| Brain and central nervous system (C70-C72, C75.1 and C75.3) | 2 | 0.65 | 0.16 to 2.64 | 0.70 | 0.17 to 2.89 |
| Thyroid gland (C73) | 1 | 0.73 | 0.10 to 5.30 | 1.08 | 0.14 to 8.21 |
| Lymphoid and haematopoietic tissue (C81-C96 and D45-D47) | 11 | 1.59 | 0.87 to 2.91 | 1.62 | 0.87 to 3.02 |
| Non-Hodgkins lymphoma (C82-C85) | 7 | ||||
| Leukaemia (C91-C95 and D45-D47) | 4 | 1.73 | 0.63 to 4.75 | 1.68 | 0.60 to 4.74 |
| Chronic lymphocytic leukaemia (CLL)(C91.1) | 1 | 1.33 | 0.18 to 9.84 | 1.19 | 0.16 to 9.14 |
| Non-CLL (C91-C95 and D45-D47, except C91.1) | 3 | 1.95 | 0.61 to 6.25 | 2.00 | 0.60 to 6.66 |
| p-yr 18,463 | p-yr 678,577 | | p-yr 305,053 | | |
| Basal cell carcinoma of the skin | 15 | 1.52 | 0.90 to 2.55 | ||
Abbreviation: p-yr, person years.
Statistically significant HRs are bolded.
Number of all cancers and selected cancer sites among women only in the high - temperature geothermal areas, hazard ratio (HR), 95% confidence intervals (CI) according to comparison with the populations in warm reference area and cold reference area, adjusted for age, gender, education, and type of housing
| | |||||
|---|---|---|---|---|---|
| All sites (C00-C97 and D45-D47) | 94 | ||||
| Stomach (C16) | 3 | 1.33 | 0.42 to 4.22 | 1.55 | 0.46 to 5.14 |
| Colon, rectum and anus (C18-C21) | 7 | 1.16 | 0.54 to 2.46 | 1.24 | 0.57 to 2.70 |
| Bile and liver (C22-C24) | 1 | 1.54 | 0.21 to 11.56 | 0.82 | 0.11 to 6.17 |
| Pancreas (C25) | 4 | 2.68 | 0.96 to 7.45 | 2.26 | 0.78 to 6.52 |
| Lung and bronchus (C33-C34) | 11 | 1.56 | 0.85 to 2.86 | 1.26 | 0.68 to 2.33 |
| Bone (C40-C41) | 2 | ||||
| Melanoma (C43) | 2 | 0.85 | 0.21 to 3.46 | 0.85 | 0.20 to 3.53 |
| Other cancer of skin (C44) | 1 | 0.48 | 0.07 to 3.43 | 0.66 | 0.09 to 4.91 |
| Soft tissue sarcoma (C49) | 1 | 2.21 | 0.29 to 16.90 | 1.62 | 0.20 to 12.90 |
| Breast (C50) | 31 | ||||
| Vulva (C51) | 1 | 4.03 | 0.50 to 32.36 | 2.96 | 0.34 to 25.58 |
| Cervix uteri (C53) | 2 | 0.85 | 0.21 to 3.45 | 1.04 | 0.25 to 4.37 |
| Uterus (C54-C55) | 3 | 0.82 | 0.26 to 2.60 | 0.88 | 0.27 to 2.82 |
| Ovary (C56-C57) | 5 | 1.25 | 0.51 to 3.05 | 1.25 | 0.50 to 3.12 |
| Kidney (C64-C66) | 3 | 1.04 | 0.33 to 3.29 | 1.27 | 0.39 to 4.16 |
| Bladder (C67) | 1 | 0.67 | 0.09 to 4.85 | 0.65 | 0.09 to 4.85 |
| Brain and central nervous system (C70-C72, C75.1 and C75.3) | 3 | 1.01 | 0.32 to 3.20 | 1.11 | 0.34 to 3.62 |
| Thyroid gland (C73) | 5 | 1.92 | 0.78 to 4.74 | 1.65 | 0.65 to 4.18 |
| Cancer without specification of site (C80) | 1 | 0.55 | 0.08 to 4.01 | 0.56 | 0.08 to 4.11 |
| Lymphoid and haematopoietic tissue (C81-C96 and D45-D47) | 7 | 1.46 | 0.68 to 3.12 | 1.66 | 0.76 to 3.63 |
| Hodgkins lymphoma (C81) | 1 | 2.13 | 0.28 to 16.22 | 4.42 | 0.49 to 39.63 |
| Non-Hodgkins lymphoma (C82-C85) | 5 | ||||
| Immunoproliferative diseases (C88) | 1 | 4.38 | 0.54 to 35.34 | 11.92 | 0.72 to 197.59 |
| p-yr 18,143 | p-yr 641,643 | | p-yr 276,719 | | |
| Basal cell carcinoma of the skin | 15 | 1.24 | 0.74 to 2.08 | 1.45 | 0.85 to 2.47 |
Abbreviation: p-yr, person years.
* 95% CI computed with bootstrap method were wide and included unity.
Statistically significant HRs are bolded.